Clinical Performance Evaluation of a SARS-CoV-2 Rapid Antibody Test for Determining Past Exposure to SARS-CoV-2

Peter Findeisen[a], Hugo Stiegler[b], Eloisa Lopez-Calle[c], Tanja Schneider[d], Eva Urlaub[c], Johannes Hayer[c], Claudia Zemmrich[e,f#]

[a]MVZ Labor Dr. Limbach & Kollegen GbR, Heidelberg, Germany

[b]MVZLM - Medizinisches Versorgungszentrum für Labormedizin und Mikrobiologie Ruhr GmbH, 45138 Essen, Germany

[c]Roche Diagnostics GmbH, Mannheim, Germany

[d]Roche Diagnostics GmbH, Penzberg, Germany

[e#]Institute for Pharmacology and Preventive Medicine, Menzelstrasse 21, 15831 Mahlow, Germany

[f]Roche Diagnostics International Ltd. Rotkreuz, Switzerland

Corresponding author: Claudia Zemmrich, Institute for Pharmacology and Preventive Medicine, Menzelstrasse 21, 15831 Mahlow, Germany, claudia.zemmrich@ippmed.de

Running title: Performance of a SARS-CoV-2 rapid antibody test

Target: Journal of Clinical Microbiology

Abstract

The true prevalence and population seropositivity of SARS-CoV-2 infection remains unknown, due to the number of asymptomatic infections and limited access to high-performance antibody tests. To control the COVID-19 pandemic it is crucial to understand the true seroprevalence, but not every region has access to extensive centralized PCR and serology testing. Currently available rapid antibody tests lack the accuracy needed for recommendation by health authorities. To fill this gap, we analyzed and validated the clinical performance of a new point-of-care SARS-CoV-2 Rapid Antibody Assay, a chromatographic immunoassay for qualitative detection of IgM/IgG antibodies for use in near-patient settings. Analysis was performed using 42 Anti-SARS-Cov-2 positive (CoV+) and 92 Anti-SARS-Covid-2 negative (CoV-) leftover samples from before December 2019, using the Elecsys® Anti-SARS-CoV-2 as the reference assay. Analytical specificity was tested using leftover samples from individuals with symptoms of common cold collected before December 2019. The SARS-CoV-2 Rapid Antibody Test was 100.0% (95% CI 91.59–100.00) sensitive and 96.74% (95% CI 90.77–99.32) specific with an assay failure rate of 0.00%. No cross-reactivity was observed against the common cold panel. Method comparison was additionally conducted by two external laboratories, using 100 CoV+/275 CoV- samples, also comparing whole blood versus plasma matrix. The comparison demonstrated for plasma 96.00% positive/96.36% negative percent agreement with the Elecsys Anti-SARS-CoV-2 and overall 99.20% percent agreement between whole blood and EDTA plasma. The SARS-CoV-2 Rapid Antibody Test demonstrated similar clinical performance to the manufacturer's data and to a centralized automated immunoassay, with no cross-reactivity to common cold panels.

Key words: SARS-CoV-2, rapid antibody test, past exposure

Introduction

The global COVID-19 pandemic created an urgent unmet clinical need to investigate reliable diagnostic tools for patients, as well as understand the extent of exposure and spread of infection among wider populations (1-3). Acute diagnosis of the COVID-19 infection is based on identification of viral RNA via PCR from swab samples, which is detectable from symptom onset for approximately four weeks (2, 4). As is known from localized testing during outbreaks, many people who are infected with the virus do not present with any clinical symptoms – current estimates suggest around 30% of seropositive individuals are asymptomatic (5-7). Those individuals carry the virus and potentially spread it to others, who may react with a severe COVID-19 disease (8). No region in the world can perform PCR testing of every patient with common cold symptoms or who has had contact with a suspected COVID-19 patient. In addition to clinical testing of individuals with suspected COVID-19 for direct virus detection, surveillance strategies need to combine several diagnostic techniques to monitor disease kinetics in wider populations (2, 9). To control the pandemic, it seems crucial to investigate who has already had an infection and has developed antibodies as an immune response, and vice versa, who is still vulnerable to an infection (10-14).

Antibody tests are not intended to diagnose an acute COVID-19 infection, more specific diagnostic methods should be performed to obtain this (2). Ongoing research on the level and duration of immunity of seropositive persons will add further value to the clinical and epidemiological interpretation of positive antibody testing results. Preliminary data suggest that high affinity antibody tests show good correlation with neutralizing activity (15).

64 Based on current evidence, immunoglobulin M (IgM) antibodies are detectable within 5 days
65 after symptom onset and immunoglobulin G (IgG) antibodies within 5–7 days (4, 16-23).
66 Depending on the applied method, seroconversion is observed after a median of 10–13 days
67 after symptom onset for IgM and 12–14 days for IgG, and maximum for both is reached after 2
68 weeks (4, 16, 19-26). Individual levels and kinetics of both IgM and IgG are highly variable,
69 which is why simultaneous detection of both is recommended.

70 Currently available rapid antibody tests require improved accuracy before being recommended
71 by competent authorities and used by healthcare professionals (HCPs) in the wider population
72 (2, 3). The US Food and Drug Administration (FDA) released technical requirements for antibody
73 tests on April 4, 2020, that include a specificity of ≥ 95% and cross-reactivity testing for
74 common cold and other coronaviruses (27). There are different high-throughput Anti-SARS-
75 CoV-2 antibody tests available; the assay selected as the reference for our test (Elecsys Anti-
76 SARS-CoV-2 Immunoassay) is based on electrochemiluminescence (ECLIA), using a double-
77 antigen sandwich test principle and a recombinant protein representing the antigen for the
78 determination of antibodies to SARS-CoV-2, namely the nucleocapsid protein (N) (28). It
79 provides a qualitative result with a sensitivity of 100.0% (95% CI 88.10–100.0) at ≥ 14 days after
80 PCR confirmation and a specificity of 99.81% (95% CI 99.65–99.91) (28).
81

82 Rapid tests, also called point-of-care (PoC) tests, combine immunoassay and chromatography
83 for a qualitative detection of antibodies. The selected test *(Anti-SARS-CoV-2 Rapid Antibody*
84 *Test [SD Biosensor, Chungcheongbuk-do, Republic of Korea])* is a CE marked lateral flow assay
85 displaying a visual 'yes/no' answer for the selective detection of specific IgG and/or IgM
86 antibodies to SARS-CoV-2, with two separate colored bands for IgG and IgM (29). The
87 manufacturer states the specificity is 98.65% and sensitivity beyond 14 days after symptom

88 onset of 99.03%, tested on 103 PCR-confirmed CoV+ and 222 CoV- samples (29). The samples
89 had also been tested for early sensitivity between 7 and 14 days after symptom onset with a
90 result of 92.59%. SD Biosensor has performed several cross-reactivity studies involving
91 numerous specimens, including influenza A and B.
92
93 In this study series, we further validated and extended the manufacturers' clinical performance
94 and cross-reactivity data and externally performed a matrix and method comparison to gain
95 additional data on the overall assay performance.

96 **Materials and Methods**

97 ***The assay***

98 The assay ***(Figure 1)*** needs 10 µl human serum or plasma, or 20 µl whole venous or capillary
99 blood sample to be filled into the preformed well of the test device. Three pre-coated lines
100 mark the "C" control line, and the "G" and "M" test lines for IgG and IgM. Monoclonal chicken
101 IgY antibody is coated on the "C" region, and monoclonal anti-human IgG antibody and
102 monoclonal anti-human IgM antibody are coated on the "G" and "M" test line region. During
103 the test, SARS-CoV-2-specific antibodies in the sample interact with recombinant SARS-CoV-2
104 protein (nucleocapsid and spike protein) conjugated with colloidal gold particles forming
105 antibody–antigen gold particle complexes. This complex migrates on the membrane via
106 capillary action until the "M" and "G" test line, where it will be captured by the monoclonal
107 anti-human IgG antibody or monoclonal anti-human IgM antibody. A violet test line would be
108 visible in the result window if SARS-CoV-2-specific antibodies are present in the sample. The
109 intensity of the colored test line varies depending upon the amount of SARS-CoV-2 antibodies

110 present in the sample. Even if the color is faint, the test result should be interpreted as a
111 positive result. The control line is used as procedural control and should always appear if the
112 test procedure is performed properly and the test reagents are working.

113 ***Study design***

114 A performance analysis was conducted at Roche Diagnostics (Penzberg, Mannheim, Germany)
115 using 42 Elecsys Anti-SARS-CoV-2 confirmed CoV+ and 92 leftover samples from healthy donors,
116 collected before December 2019 and additionally confirmed by the Elecsys Anti-SARS-CoV-2
117 CoV- (56 lithium heparin plasma, 36 EDTA plasma). Cross-reactivity testing was conducted with
118 18 samples from individuals expressing signs and symptoms of common cold (i.e. sore throat,
119 cough, fever) collected before December 2019. Additional matrix equivalence and read-out
120 time analysis captured 159 Elecsys referenced CoV- samples, consisting of 55 heparin plasma,
121 55 EDTA plasma and 49 serum samples.

122 Additionally, an independent comparison was performed with matched EDTA plasma and
123 whole blood samples from a total of 375 anonymized leftover samples at two external testing
124 sites. In total, 100 samples tested positive for SARS-CoV-2 antibodies by the Elecsys anti–SARS-
125 CoV2 immunoassay and 275 negative samples from before December 2019 and additionally
126 tested negative (25 CoV+/75 negative- subjects at MVZLM Ruhr GmbH, Essen and 75 CoV+/200
127 negative subjects at MVZ Labor Dr. Limbach & Kollegen GbR Heidelberg). No information on
128 PCR result or time of sample collection related to symptom onset was available. All samples
129 were analyzed with the Anti-SARS-CoV-2 Rapid Antibody Assay and results were compared
130 directly with the EDTA plasma sample from the Elecsys Anti-SARS-CoV-2 Assay (see Figure 1 for
131 workflow).

132 All investigations were performed according in a single determination and according to the
133 manufacturer's instructions for use.

134 ***Statistical analyses***

135 For sensitivity and specificity, point estimates and 95% CI values were calculated. To determine
136 positive and negative percent agreement (PPA and NPA), the Elecsys Anti-SARS-CoV-2 result
137 was used as comparator: »Non-reactive« (cut off index [COI] < 1.0) was a negative result and
138 »Reactive« (COI ≥ 1.0) a positive result. The rapid test was considered positive in case either IgG
139 or IgM showed a colored line, even if the line was faint. The Clopper–Pearson exact method
140 was used for the calculation of the two-sided 95% confidence intervals (CIs).

141 ***Ethics and conformity declaration***

142 The study was conducted in accordance with applicable regulations, including relevant
143 European Union directives and regulations, and the principles of the Declaration of Helsinki. All
144 samples were anonymized leftover specimens. For the samples tested at Roche Diagnostics, a
145 statement was obtained from the Ethics Committee of the Landesärztekammer Bayern
146 confirming that there are no objections against the transfer and the coherent use of the
147 anonymized leftover samples. For the samples tested in MVZLM Ruhr GmbH (Essen) and at
148 MVZ Labor Dr. Limbach & Kollegen GbR (Heidelberg) no ethics committee vote is required in
149 accordance with MPG (Medizinproduktegesetz Deutschland).

150

151 ***Data availability***

152 Qualified researchers may request access to individual patient level data through the clinical
153 study data request platform (https://vivli.org/). Further details on Roche's criteria for eligible

154 studies are available here: https://vivli.org/members/ourmembers/. For further details on
155 Roche's Global Policy on the Sharing of Clinical Information and how to request access to
156 related clinical study documents, see here:
157 https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_tria
158 ls/our_commitment_to_data_sharing.htm.

159 **Results**

160 ***Clinical performance evaluation***

161 The assay presented a qualitative visual test result without the need for a read-out instrument
162 like other rapid antibody devices on the market. Some lines were quite faint, and according to
163 manufacturer's instruction they have been interpreted as a positive result. Handling was easy
164 with one sample-transfer step and three drops of buffer dropped into the well after the blood
165 sample; the results read at 10–15 minutes. Except quality control material, lancets and a
166 transferring pipette for 10 µl, everything needed to conduct the test was included into the test
167 package. All test cassettes were correctly assembled, opening the foil pouch was easy without
168 danger of destroying the desiccant and no membranes were scratched.

169 A total of 42 left-over samples with prior Elecsys-confirmed positive SARS-CoV-2 antibody
170 detection were included in the sensitivity analysis. The overall sensitivity was 100.0% (95 % CI
171 91.59–100.0) (Table 1). A total of 92 samples from healthy donors before December 2019
172 presented an overall specificity of 96.74% (95% CI 90.77–99.32) with no difference between
173 EDTA and lithium-heparin plasma: 97.22% (95% CI: 85.47–99.93)/96.43% (95% CI 87.69–99.56).

174 An additional matrix evaluation and read-out time analysis was performed with 159 SARS-CoV-2
175 negative samples to confirm equal results throughout the pre-defined read-out time window.

176 At read out times ≤10 minutes specificity was slightly higher versus at 15 minutes (Table 2),
177 however detectable signals were 'weaker' or less well defined at ≤10 minutes compared with
178 15 minutes read out time. No relevant performance differences were noticed between serum,
179 heparin and EDTA plasma (Table 2).

180 Cross-reactivity was tested at 18 samples from a common cold panel, collected before
181 December 2019 without further information on the exact pathogens of the specimens. For all
182 18 measurements, a colored control line was obtained, indicating that the test worked
183 properly. On the test lines for IgG and IgM no color appeared, thus leading to a negative result
184 and resulting in a specificity of 100.0% (95 % CI 81.47–100.0%). The results demonstrated that
185 the test is not reacting with antibodies directed against related pathogens from common cold
186 infections.

187 ***External method and matrix comparison***

188 Total results for both testing methods (plasma/whole blood samples) were 96.00% (95 % CI
189 90.07–98.90) / 94.00% (95% CI 87.40–97.77) for positive percent agreement rate and 96.36%
190 (95% CI 93.41–98.24) / 96.00 % (95% CI 92.96–97.99) for negative percent agreement rate. The
191 sample numbers per matrix and per immunoglobulin class for the samples confirmed by the
192 Elecsys test and the numbers differing from the Elecsys result are summarized in Table 3. The
193 overall percent agreement rate between whole blood and EDTA plasma was 99.20% (95% CI
194 97.68–99.83), the positive/negative percent agreement rates for whole blood versus EDTA
195 plasma were 98.11 % (95% CI 93.35–99.77) / 99.63 (95% CI 97.95–99.99).

196 A total of 10 EDTA samples and 11 whole blood samples were detected antibody positive by the
197 Anti-SARS-CoV-2 Rapid Antibody Assay but antibody negative by the Elecsys assay, see Table 4a
198 for the respectively detected immunoglobulin classes and the respective signal intensity on the

199 11 rapid tests. 96 plasma and 94 whole blood samples out of 100 Elecsys-positive samples were
200 detected positive by the rapid test, see Table 4b for the respective immunoglobulin classes and
201 signal intensity of the six rapid test results. The matrix comparison for the Anti-SARS-CoV-2
202 Rapid Antibody Assay found of 106 plasma samples with an antibody positive test result,
203 included two samples which had negative tests results with whole blood. One out of 269
204 negative test results on the rapid test with plasma displayed a positive result with whole blood.

205 **Discussion**

206 The COVID-19 pandemic has created an urgent need for antibody testing of large populations to
207 determine seroprevalence and potential immunity, which will be of more importance if more
208 conclusive scientific data on correlation between these factors become available (2, 3, 26, 30,
209 31). The anticipated need for high testing capacities in PoC settings outside of large hospitals,
210 calls for the development and validation of high-performance rapid antibody tests as reliable
211 diagnostic instruments, in addition to the centralized antibody tests available. The evaluated
212 Anti-SARS-CoV-2 Rapid Antibody Test complies with the acceptance criteria, defined by the FDA
213 EUA on April 4, 2020, for SARS-CoV-2 antibody test developments (27). Our internal clinical
214 performance evaluation confirmed the manufacturers' reported clinical sensitivity of the test
215 with an uncharacterized cohort of antibody positive samples from a population with unknown
216 time from symptom onset, which may reflect the typical clinical scenario for the test indication.
217 The external comparison confirmed high agreement of both the Elecsys assay and the Anti-
218 SARS-CoV-2 Rapid Antibody Test, also with no confirmed PCR result and time of sampling from
219 symptom onset unknown. For both the internal and external evaluation, samples could be
220 mixed, with some collected early after symptom onset. Both tests claim less than 100 %

221 sensitivity <14 days after symptom onset (28, 29). The Elecsys Anti-SARS-CoV-2 Antibody Test
222 measures high-affinity IgG/IgM antibodies directed at the nucleocapsid antigen, with an
223 excellent sensitivity of 100.0% (95% CI 88.1–100.0) at ≥ 14 days after PCR confirmation (28). The
224 rapid test has been developed detecting both nucleocapsid- and spike protein-associated
225 antibodies to increase test accuracy compared with centralized serological assays, which
226 typically perform better than rapid tests. (29). A limitation of this study is that samples were
227 not differentiated according to time of collection after symptom onset, as such some of the
228 false positive samples might actually be true positives, but were not detected by the Elecsys
229 assay and most likely indicate an early antibody response with low affinity antibodies. For SARS-
230 CoV-2 tests high specificity is a priority, particularly in low prevalence settings (30), as such it
231 would be interesting to further evaluate the interpretation of the low positive samples at the
232 rapid test, particularly for samples that were IgM positive only, to determine if these reflect
233 non-specific binding, or true early detection. Further assessment with serial samples taken from
234 COVID-19 patients from early infection phase onwards will help to better understand this.

235 The investigated Anti-SARS-CoV-2 Rapid Antibody Test provided readily evaluable results,
236 regardless of sample type (whole blood or EDTA plasma) and independent of any read-out time
237 between 10 and 15 minutes, as stated in the instructions for use. Those positive practical
238 aspects could enable potential use outside medical environments. The assay is currently
239 intended for professional use in laboratory and PoC environments as an aid in identifying
240 individuals with an adaptive immune response to SARS-CoV-2, indicating prior infection.

241 In these studies, the SARS-CoV-2 Rapid Antibody Test demonstrates excellent clinical
242 performance without cross-reactivity to common cold samples and results comparable to data
243 of an automated high-performance immunoassay (Elecsys). Our data confirm and extend the

manufacturers' performance data and add further details on matrix and method comparisons. Available data support its use as a reliable diagnostic instrument for SARS-CoV-2 IgM and IgG antibody detection in near-patient settings with potential extended usability outside medical environments.

Acknowledgements

The authors would like to acknowledge the contributions of Rabea Held, Regina Draude, Marcus Pollok (Roche Diagnostics GmbH, Mannheim, Germany) for testing, data acquisition in the laboratory and preliminary data analysis. In addition, thanks to Imola Szebenyi, Oscar Gutierrez-Sanz, Miriam Hübner, Ludwig Pollich, Nicolai Bluthardt, Andreas Aristow (Roche Diagnostics GmbH, Penzberg, Germany) for the measurements of the clinical and cross-reactivity samples as part of the study conducted at Roche Diagnostics. Thanks to John Burden (Roche Diagnostics International Ltd. Rotkreuz, Switzerland), Sven Groesgen (Roche Diagnostics GmbH, Mannheim, Germany) and Christine Jung (Roche Diagnostics GmbH, Penzberg, Germany) for planning, set-up and analysis of the external evaluation. The authors would also like to acknowledge Matthias Metz and Daria Glukhova for conducting the measurements with the Elecsys SARS-CoV-2 method as part of the study at Roche Diagnostics.

Conflicts of interest/financial disclosures

Eloisa Lopez-Calle, Tanja Schneider, Eva Urlaub, Johannes Hayer, are all employees of Roche Diagnostics. Claudia Zemmrich works as a freelance contractor for Roche Diagnostics.

263 **References**

264 1. The World Health Organization. 2020. Immunity passports in the context of COVID-19.
265 https://www.who.int/news-room/commentaries/detail/immunity-passports-in-the-context-of-
266 covid-19. Accessed July 2020.
267 2. The European Centre for Disease Prevention and Control. 2020. Diagnostic testing and
268 screening for SARS-CoV-2. https://www.ecdc.europa.eu/en/covid-19/latest-
269 evidence/diagnostic-testing. Accessed July 2020.
270 3. The US Centers for Disease Prevention and Control. 2020. Interim guidelines for COVID-19
271 antibody testing. https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antibody-tests-
272 guidelines.html. Accessed June 2020.
273 4. Sethuraman N, Jeremiah SS, Ryo A. 2020. Interpreting diagnostic tests for SARS-CoV-2. JAMA
274 doi:10.1001/jama.2020.8259.
275 5. Pollan M, Perez-Gomez B, Pastor-Barriuso R, Oteo J, Hernan MA, Perez-Olmeda M, Sanmartin JL,
276 Fernandez-Garcia A, Cruz I, Fernandez de Larrea N, Molina M, Rodriguez-Cabrera F, Martin M,
277 Merino-Amador P, Leon Paniagua J, Munoz-Montalvo JF, Blanco F, Yotti R, Group E-CS. 2020.
278 Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based
279 seroepidemiological study. Lancet doi:10.1016/S0140-6736(20)31483-5.
280 6. Sandri MT, Azzolini E, Torri V, Carloni S, Tedeschi M, Castoldi M, Mantovani A, Rescigno M. 2020.
281 IgG serology in health care and administrative staff populations from 7 hospital representative
282 of different exposures to SARS-CoV-2 in Lombardy, Italy. medRxiv
283 doi:10.1101/2020.05.24.20111245:2020.05.24.20111245.
284 7. Mizumoto K, Kagaya K, Zarebski A, Chowell G. 2020. Estimating the asymptomatic proportion of
285 coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship,
286 Yokohama, Japan, 2020. Euro Surveill 25;(10):2000180

287 8. European Centre for Disease Prevention and Control. 2020. Transmission of COVID-19.
288 https://www.ecdc.europa.eu/en/covid-19/latest-evidence/transmission. Accessed July 2020.
289 9. The World Health Organization. 2020. Surveillance strategies for COVID-19 human infection:
290 interim guidance. https://www.who.int/publications/i/item/surveillance-strategies-for-covid-19-
291 human-infection. Accessed July 2020.
292 10. Althoff KN, Coburn SB, Nash D. 2020. Contact tracing: Essential to the public health response
293 and our understanding of the epidemiology of COVID-19. Clin Infect Dis
294 doi:10.1093/cid/ciaa757.
295 11. Fiore VG, DeFelice N, Glicksberg BS, Perl O, Shuster A, Kulkarni K, O'Brien M, Pisauro MA, Chung
296 D, Gu X. 2020. Containment of future waves of COVID-19: simulating the impact of different
297 policies and testing capacities for contact tracing, testing, and isolation. medRxiv
298 doi:10.1101/2020.06.05.20123372.
299 12. MacIntyre CR. 2020. Case isolation, contact tracing, and physical distancing are pillars of COVID-
300 19 pandemic control, not optional choices. Lancet Infect Dis doi:10.1016/S1473-3099(20)30512-
301 0.
302 13. Sen-Crowe B, McKenney M, Elkbuli A. 2020. COVID-19 laboratory testing issues and capacities as
303 we transition to surveillance testing and contact tracing. Am J Emerg Med
304 doi:10.1016/j.ajem.2020.05.071.
305 14. Steinbrook R. 2020. Contact Tracing, Testing, and Control of COVID-19-Learning From Taiwan.
306 JAMA Intern Med doi:10.1001/jamainternmed.2020.2072.
307 15. Wu F, Wang A, Liu M, Wang Q, Chen J, Xia S, Ling Y, Zhang Y, Xun J, Lu L, Jiang S, Lu H, Wen Y,
308 Huang J. 2020. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient
309 cohort and their implications. medRxiv
310 doi:10.1101/2020.03.30.20047365:2020.03.30.20047365.
311 16. Guo L, Ren L, Yang S, Xiao M, Chang, Yang F, Dela Cruz CS, Wang Y, Wu C, Xiao Y, Zhang L, Han L,
312 Dang S, Xu Y, Yang Q, Xu S, Zhu H, Xu Y, Jin Q, Sharma L, Wang L, Wang J. 2020. Profiling early

313 humoral response to diagnose novel coronavirus disease (COVID-19). Clin Infect Dis
314 doi:10.1093/cid/ciaa310.
315 17. Liu L, Liu W, Wang S, Zheng S. 2020. A preliminary study on serological assay for severe acute
316 respiratory syndrome coronavirus 2 (SARS-CoV-2) in 238 admitted hospital patients. medRxiv
317 doi:10.1101/2020.03.06.20031856:2020.03.06.20031856.
318 18. Long Q-X, Deng H-J, Chen J, Hu J, Liu B-Z, Liao P, Lin Y, Yu L-H, Mo Z, Xu Y-Y, Gong F, Wu G-C,
319 Zhang X-C, Chen Y-K, Li Z-J, Wang K, Zhang X-L, Tian W-G, Niu C-C, Yang Q-J, Xiang J-L, Du H-X, Liu
320 H-W, Lang C, Luo X-H, Wu S-B, Cui X-P, Zhou Z, Wang J, Xue C-J, Li X-F, Wang L, Tang X-J, Zhang Y,
321 Qiu J-F, Liu X-M, Li JJ, Zhang D-C, Zhang F, Cai X-F, Wang D, Hu Y, Ren J-H, Tang N, Liu P, Li Q,
322 Huang A-L. 2020. Antibody responses to SARS-CoV-2 in COVID-19 patients: the perspective
323 application of serological tests in clinical practice. medRxiv
324 doi:10.1101/2020.03.18.20038018:2020.03.18.20038018.
325 19. Lou B, Li T, Zheng S, Su Y, Li Z, Liu W, Yu F, Ge S, Zou Q, Yuan Q, Lin S, Hong C, Yao X, Zhang X, Wu
326 D, Zhou G, Hou W, Li T, Zhang Y, Zhang S, Fan J, Zhang J, Xia N, Chen Y. 2020. Serology
327 characteristics of SARS-CoV-2 infection since the exposure and post symptoms onset. medRxiv
328 doi:10.1101/2020.03.23.20041707:2020.03.23.20041707.
329 20. Okba NMA, Marcel AM, Wentao L, Chunyan W, Corine HG, Victor MC, Mart ML, Reina SS, Erwin
330 de B, Felicity DC, Yazdan Y, Quentin Le H, Diane D, Nadhira H-F, Chantal BEMR, Berend-Jan B,
331 Christian D, Marion PGK, Bart LH. 2020. Severe acute respiratory syndrome coronavirus
332 2–Specific antibody responses in coronavirus disease 2019 patients. Emerging Infectious Disease
333 journal 26(7):1478–88..
334 21. Tan W, Lu Y, Zhang J, Wang J, Dan Y, Tan Z, He X, Qian C, Sun Q, Hu Q, Liu H, Ye S, Xiang X, Zhou
335 Y, Zhang W, Guo Y, Wang X-H, He W, Wan X, Sun F, Wei Q, Chen C, Pan G, Xia J, Mao Q, Chen Y,
336 Deng G. 2020. Viral Kinetics and Antibody Responses in Patients with COVID-19. medRxiv
337 doi:10.1101/2020.03.24.20042382:2020.03.24.20042382.

338 22. To KK-W, Tsang OT-Y, Leung W-S, Tam AR, Wu T-C, Lung DC, Yip CC-Y, Cai J-P, Chan JM-C, Chik
339 TS-H, Lau DP-L, Choi CY-C, Chen L-L, Chan W-M, Chan K-H, Ip JD, Ng AC-K, Poon RW-S, Luo C-T,
340 Cheng VC-C, Chan JF-W, Hung IF-N, Chen Z, Chen H, Yuen K-Y. 2020. Temporal profiles of viral
341 load in posterior oropharyngeal saliva samples and serum antibody responses during infection
342 by SARS-CoV-2: an observational cohort study. The Lancet Infectious Diseases 20:565-574.
343 23. Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, Wang X, Yuan J, Li T, Li J, Qian S, Hong C, Wang F, Liu
344 Y, Wang Z, He Q, Li Z, He B, Zhang T, Fu Y, Ge S, Liu L, Zhang J, Xia N, Zhang Z. 2020. Antibody
345 responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin Infect Dis
346 doi:10.1093/cid/ciaa344.
347 24. Amanat F, Stadlbauer D, Strohmeier S, Nguyen T, Chromikova V, McMahon M, Jiang K, Asthagiri-
348 Arunkumar G, Jurczyszak D, Polanco J, Bermudez-Gonzalez M, Kleiner G, Aydillo T, Miorin L,
349 Fierer D, Lugo LA, Milunka Kojic E, Stoever J, Liu STH, Cunningham-Rundles C, Felgner PL,
350 Caplivski D, Garcia-Sastre A, Cheng A, Kedzierska K, Vapalahti O, Hepojoki J, Simon V, Krammer
351 F, Moran T. 2020. A serological assay to detect SARS-CoV-2 seroconversion in humans. medRxiv
352 doi:10.1101/2020.03.17.20037713:2020.03.17.20037713.
353 25. Xiang F, Wang X, He X, Peng Z, Yang B, Zhang J, Zhou Q, Ye H, Ma Y, Li H, Wei X, Cai P, Ma WL.
354 2020. Antibody detection and dynamic characteristics in patients with COVID-19. Clin Infect Dis
355 doi:10.1093/cid/ciaa461.
356 26. Zhang J, Liu J, Li N, Liu Y, Ye R, Qin X, Zheng R. 2020. Serological detection of 2019-nCoV respond
357 to the epidemic: A useful complement to nucleic acid testing. medRxiv
358 doi:10.1101/2020.03.04.20030916:2020.03.04.20030916.
359 27. Administration UFaD. 2020. Policy for coronavirus disease-2019 tests during the public health
360 emergency (Revised). https://www.fda.gov/regulatory-information/search-fda-guidance-
361 documents/policy-coronavirus-disease-2019-tests-during-public-health-emergency-revised.
362 28. Roche Diagnostics GmbH. 2020. Elecsys Anti-SARS-CoV-2 Method Sheet.
363 29. SD Biosensor. 2020. SARS-CoV-2 Rapid Antibody Test Method Sheet.

364 30. Ozcurumez MK, Ambrosch A, Frey O, Haselmann V, Holdenrieder S, Kiehntopf M, Neumaier M,
365 Walter M, Wenzel F, Wolfel R, Renz H, Chemistry C-TFotGSfC, Laboratory M. 2020. SARS-CoV-2
366 antibody testing-questions to be asked. J Allergy Clin Immunol 146:35-43.
367 31. Theel ES, Slev P, Wheeler S, Couturier MR, Wong SJ, Kadkhoda K. 2020. The Role of Antibody
368 Testing for SARS-CoV-2: Is There One? J Clin Microbiol doi:10.1128/JCM.00797-20.

369

370 **Table 1. Performance data of the manufacturer, internal clinical performance test, matrix equivalence test and external method comparison**

	SD Biosensor data**, % (95% CI)	Internal test, % (95% CI)	Matrix evaluation, % (95% CI)	External comparison (95% CI)
Samples tested, n	195+ / 222-	42+ / 92-	159-	100+ / 275-
Reference method	PCR	Elecsys® Anti-SARS-CoV-2 Antibody Assay	Elecsys® Anti-SARS-CoV-2 Antibody Assay	*n.a.*
Specificity versus Reference method	98.65 (96.10–99.72)	96.74 (90.77–99.32)	96.23 (91.97–98.60)	96.00*** (90.07–98.90)
Sensitivity versus Reference method • 7–14 days*	92.59 (82.11–97.94)			
• > 14 days*	99.03 (94.71–99.98)			
• All time periods		100 (91.59–100.00)	n.a.	96.36*** (93.41–98.24)

371

372 n.a. not applicable; +/-, positive/negative for SARS-CoV-2 determined by respective reference method

373 *Post symptom onset; **according to Anti-SARS-CoV-2 Rapid Antibody Assay Method sheet; ***positive/negative percent agreement with

374 Elecsys Anti-SARS-CoV-2 in EDTA plasma, data in italics as generated by comparative analysis, not clinical performance analysis

375

376 **Table 2. Matrix evaluation and read-out time analysis**

		Read out time			
		8 mins	**10 mins**	**12 mins**	**15 mins**
Total	**Number of samples test (negative)**	159	159	159	159
	False positive	4	5	6	6
	Specificity % (95% CI)	97.48 (93.68–99.31)	96.86 (92.81–98.97)	96.23 (91.97–98.60)	96.23 (91.97–98.60)
Serum	**Number of samples test (negative)**	49	49	49	49
	False positive	1	2	2	2
	Specificity % (95% CI)	97.96 (89.15–99.95)	95.92 (86.02–99.50)	95.92 (86.02–99.50)	95.92 (86.02–99.50)
Heparin plasma	**Number of samples test (negative)**	55	55	55	55
	False positive	1	1	2	2
	Specificity % (95% CI)	98.18 (90.28–99.95)	98.18 (90.28–99.95)	96.36 (87.47–99.56)	96.36 (87.47–99.56)
EDTA plasma	**Number of samples test (negative)**	55	55	55	55
	False positive	2	2	2	2
	Specificity % (95% CI)	96.36 (87.47–99.56)	96.36 (87.47–99.56)	96.36 (87.47–99.56)	96.36 (87.47–99.56)

7 **Table 3. External comparison to Elecsys Anti-SARS-CoV-2 per matrix and immunoglobulin**

8 **class**

	Number of results (Whole blood)				Number of results (EDTA Plasma)			
	IgM	**IgG**	**IgM+IgG**	**Total**	**IgM**	**IgG**	**IgM+IgG**	**Total**
SARS-CoV-2 positive (confirmed by Elecsys)	1	57	36	94	0	54	42	96
SARS-CoV-2 negative (confirmed by Elecsys)	0	0	0	264	0	0	0	265
False positive results (compared to Elecsys)	4	5	2	11	3	5	2	10
False negative results (compared to Elecsys)	0	0	0	6	0	0	0	4
OPA (95%CI)	95.47% (92.84–97.34)				96.27% (93.82–97.94)			
PPA (95% CI)	94.00% (87.40–97.77)				96.00% (90.07–98.90)			
NPA (95% CI)	96.00% (92.96–97.99)				96.36% (93.41–98.24)			

9 OPA, overall percentage agreement; PPA, positive percentage agreement; NPA, negative

0 percentage agreement

381 **Table 4a: Method comparison: Discrepant positive samples - detected signal intensity and immunoglobulin class**

Sample number	Rapid AB results – whole blood		Rapid AB results – EDTA plasma		Elecsys results (EDTA plasma)	
	IgG	IgM	IgG	IgM	Result	COI
1	-	X (weak)	-	X (weak)	Non-reactive	0.089
2	-	X (weak)	-	X (weak)	Non-reactive	0.119
3	-	X (weak)	-	X (weak)	Non-reactive	0.089
4	X (weak)	-	X (weak)	-	Non-reactive	0.079
5	-	X (weak)	-	-	Non-reactive	0.069
6	X (weak)	X (weak)	X (weak)	X (weak)	Non-reactive	0.229
7	X	-	X	-	Non-reactive	0.146
8	X (weak)	-	X (weak)	-	Non-reactive	0.221
9	X (weak)	-	X (weak)	-	Non-reactive	0.269
10	X	X	X	X	Non-reactive	0.189
11	X	-	X	-	Non-reactive	0.378

382 AB, antibody

383 **Table 4b Method comparison: Discrepant negative samples - detected signal intensity and immunoglobulin class**

Sample number	**Rapid AB results – whole blood**		**Rapid AB results – EDTA plasma**		**Elecsys results (EDTA plasma)**	
	IgG	IgM	IgG	IgM	Result	COI
1	-	-	-	-	Reactive	1.21
2	-	-	-	-	Reactive	1.99
3	-	-	X (weak)	-	Reactive	39.54
4	-	-	-	-	Reactive	2.32
5	-	-	-	-	Reactive	2.34
6	-	-	X (weak)	-	Reactive	16.7

384 AB, antibody

385

Figure 1. External method and matrix comparison – workflow